FDA approves omalizumab for food allergy reactions based on NIH research

Today’s Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.

England’s MMR vaccinations up 23% following NHS initiative – Pharmaceutical Technology

Share this article Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent

April 5, 2024

FDA delays decision of Soleno’s Prader-Willi syndrome drug – Pharmaceutical Technology

The extension allows the FDA time to complete its review. Credit: izzuanroslan via Shutterstock. The US Food and Drug Administration (FDA) has delayed its decision

November 27, 2024

Compensation is key to fixing primary care shortage

Money talks. The United States faces a serious shortage of primary care physicians for many reasons, but one, in particular, is inescapable: compensation.

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.